share_log

Sharps Technology, Inc. Regains Compliance With Nasdaq Minimum Bid Price Requirement

Sharps Technology, Inc. Regains Compliance With Nasdaq Minimum Bid Price Requirement

Sharps 科技 公司 重新符合 納斯達克 最低 買盤 價格 要求
Quiver Quantitative ·  11/18 08:13

Sharps Technology has regained Nasdaq compliance with a minimum bid price of $1.00 per share as of November 5, 2024.

Sharps科技已於2024年11月5日恢復了納斯達克合規性,最低買盤價格爲每股1.00美元。

Quiver AI Summary

Quiver AI 概要

Sharps Technology, Inc., a medical device and pharmaceutical packaging company, announced it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share as of November 5, 2024. The company received notification from Nasdaq on November 13, 2024. CEO Robert Hayes expressed satisfaction with this compliance, emphasizing its importance for the company's future and thanking shareholders for their support during a recent reverse stock split that facilitated this outcome. Sharps specializes in advanced syringe products and has a manufacturing facility in Hungary, while also partnering with Nephron Pharmaceuticals to enhance its U.S. manufacturing capabilities.

Sharps科技公司是一家醫療器械和藥品包裝公司,宣佈其已於2024年11月5日恢復了與納斯達克最低買盤價格要求每股1.00美元的合規性。該公司於2024年11月13日收到了納斯達克的通知。首席執行官羅伯特·海耶斯對這一合規性表示滿意,強調其對公司未來的重要性,並感謝股東在最近進行的反向股票拆分期間的支持,這一拆分促進了這一結果。Sharps專注於先進的注射器產品,並在匈牙利擁有一個製造設施,同時與Nephron藥品公司合作,以增強其在美國的生產能力。

Potential Positives

潛在的積極因素

  • The company has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.
  • The CEO expressed strong optimism regarding the compliance with bid price, highlighting its importance for future opportunities for the company and its shareholders.
  • The press release acknowledges and thanks shareholders for their support during the reverse split, indicating strong investor relations and communication.
  • 該公司已恢復了與納斯達克最低買盤價格要求的合規性,確保其繼續在交易所上市。
  • 首席執行官對合規的買盤價格表示強烈樂觀,強調其對公司及其股東未來機會的重要性。
  • 新聞稿承認並感謝股東在反向拆分期間的支持,這顯示出強大的投資者關係和溝通。

Potential Negatives

潛在負面影響

  • The announcement of regaining compliance with Nasdaq's minimum bid price requirement implies that the company had previously struggled with maintaining its stock price, indicating potential underlying financial or operational weaknesses.
  • The mention of a reverse split suggests that the company resorted to this measure due to low share prices, which can be perceived negatively by investors and might signal a lack of investor confidence.
  • The extensive cautionary language regarding forward-looking statements raises concerns about the company's future performance and stability, highlighting uncertainties that could negatively affect investor sentiment.
  • 恢復符合納斯達克最低買盤價格要求的公告暗示該公司之前在維持股價方面遇到困難,這表明可能存在潛在的財務或運營弱點。
  • 提到的反向拆股表明公司因爲股價低而採取了這一措施,這可能會被投資者負面解讀,並可能顯示出缺乏投資者信心。
  • 關於前瞻性陳述的大量警示性語言引發了對公司未來表現和穩定性的擔憂,突顯出可能對投資者情緒產生負面影響的不確定性。

FAQ

FAQ

What recent compliance achievement has Sharps Technology announced?

Sharps Technology最近宣佈了什麼合規成就?

Sharps Technology announced that it has regained compliance with Nasdaq's minimum bid price requirement as of November 5, 2024.

Sharps Technology宣佈,截至2024年11月5日,已恢復符合納斯達克最低買盤價格要求。

Why is Nasdaq compliance important for Sharps Technology?

爲什麼納斯達克合規對Sharps Technology重要?

Nazdaq compliance is crucial as it enhances the Company's market presence and offers better opportunities for shareholders.

納斯達克合規至關重要,因爲它提升了公司的市場存在感,併爲股東提供了更好的機會。

What products does Sharps Technology specialize in?

Sharps Technology專注於哪些產品?

Sharps Technology specializes in patented, best-in-class smart-safety syringe products and pharmaceutical packaging solutions.

Sharps Technology專注於專利、行業領先的智能安全注射器產品和藥品包裝解決方案。

How did the reverse split help Sharps regain compliance?

反向拆股如何幫助Sharps重新獲得合規性?

The reverse split supported the increase in share price, helping Sharps regain compliance with Nasdaq's listing requirements.

反向拆股支持了股價的上漲,幫助Sharps重新獲得納斯達克的上市要求合規性。

Where is Sharps Technology's manufacturing facility located?

Sharps Technology的製造設施位於哪裏?

Sharps Technology has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its U.S. capacity.

Sharps Technology在匈牙利有一個製造設施,並與Nephron藥品公司合作擴大在美國的產能。

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

免責聲明:這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發布。


$STSS Hedge Fund Activity

$STSS對沖基金活動

We have seen 6 institutional investors add shares of $STSS stock to their portfolio, and 11 decrease their positions in their most recent quarter.

我們看到6家機構投資者在最近一個季度增加了$STSS股票的持倉,而11家則降低了他們的持倉。

Here are some of the largest recent moves:

以下是一些最近最大的交易動態:

  • ESSENTIAL PLANNING, LLC. removed 155,424 shares (-95.5%) from their portfolio in Q3 2024
  • ALPHACORE CAPITAL LLC added 84,548 shares (+2100.0%) to their portfolio in Q3 2024
  • COMPASS ION ADVISORS, LLC removed 54,546 shares (-95.5%) from their portfolio in Q3 2024
  • WALLEYE CAPITAL LLC removed 40,296 shares (-100.0%) from their portfolio in Q2 2024
  • GARDEN STATE INVESTMENT ADVISORY SERVICES LLC added 7,860 shares (+inf%) to their portfolio in Q3 2024
  • RENAISSANCE TECHNOLOGIES LLC added 6,221 shares (+inf%) to their portfolio in Q3 2024
  • HIGHTOWER ADVISORS, LLC removed 5,491 shares (-100.0%) from their portfolio in Q3 2024
  • ESSENTIAL PLANNING, LLC. 在2024年第三季度從其投資組合中移除了155,424股(-95.5%)。
  • ALPHACORE CAPITAL LLC 在2024年第三季度向其投資組合中新增了84,548股(+2100.0%)。
  • COMPASS ION ADVISORS, LLC 在2024年第三季度從其投資組合中移除了54,546股(-95.5%)。
  • WALLEYE CAPITAL LLC 在2024年第二季度從其投資組合中移除了40,296股(-100.0%)。
  • GARDEN STATE INVESTMENt ADVISORY SERVICES LLC 在2024年第三季度向其投資組合中新增了7,860股(+inf%)。
  • RENAISSANCE TECHNOLOGIES LLC 在2024年第三季度向其投資組合中新增了6,221股(+inf%)。
  • HIGHTOWER ADVISORS, LLC 在2024年第三季度從其投資組合中減持了5,491股(-100.0%)。

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

要追蹤對沖基金的股票組合,請查看Quiver Quantitative的機構持股儀表板。

Full Release

全面發佈



NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) --

Sharps Technology, Inc.

(NASDAQ: "STSS" and "STSSW") ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market ("Nasdaq") that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024.


紐約,2024年11月18日(環球新聞) --

Sharps Technology, Inc.

(納斯達克: "STSS" 和 "STSSW")("Sharps")是一家創新的器械和藥品包裝公司,提供專利的優質注射器產品。公司今天宣佈,2024年11月13日,納斯達克證券市場("納斯達克")通知公司,至2024年11月5日,公司已恢復符合納斯達克證券市場繼續上市的最低買盤價格要求,即每股1.00美元,該要求載於納斯達克上市規則5550(a)(2)。



The Company's Chief Executive Officer Robert Hayes stated, "We are extremely pleased with our bid price compliance. We view our listing on Nasdaq to be extremely important to us as a Company as it offers the Company and its shareholders the best opportunity for the future. Further, we want to thank the shareholders for their support of the reverse split that supported Sharps regaining compliance."


公司首席執行官Robert Hayes表示,"我們對我們的競價符合性非常滿意。我們認爲在納斯達克上市對我們公司非常重要,因爲這爲公司及其股東提供了最佳的未來機會。此外,我們要感謝股東對支持Sharps恢復符合性的逆向拆分的支持。"




About Sharps Technology:



關於Sharps 科技:



Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the U.S. For additional information, please visit



.


Sharps科技是一家創新的器械和藥品包裝公司,爲醫療行業提供專利、最佳安全智能注射器產品。公司的產品線專注於提供超低廢物能力,採用同時具備被動和主動安全特性的注射器科技。Sharps還提供採用專業共聚物科技設計的產品,以支持預填充注射器市場領域。公司在匈牙利設有製造設施,並與Nephron藥品公司合作,以擴大其在美國的製造能力。欲了解更多信息,請訪問



.




Forward-Looking Statements:



前瞻性聲明:



This press release contains "forward-looking statements". Forward-looking statements reflect our current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," "poised" or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.


本新聞稿包含"前瞻性聲明"。前瞻性聲明反映了我們對未來事件的當前看法。在本新聞稿中使用時,「預期」、「相信」、「估計」、「預期」、「未來」、「打算」、「計劃」、「準備」或這些術語的否定形式以及類似表達,它們與我們或我們的管理有關,可以確定前瞻性聲明。此類聲明包括但不限於本新聞稿中與我們的業務策略,未來經營業績和流動性,以及資金資源展望相關的聲明。前瞻性聲明基於我們對我們的業務,經濟和其他未來條件的當前期望和假設。由於前瞻性聲明涉及未來,因此它們受到固有的不確定性,風險和難以預測的環境變化的影響。我們的實際結果可能與前瞻性聲明所 contemplat的結果有實質性差異,它們既不是歷史事實的陳述,也不是對未來業績的保證。因此,我們警告您不要依賴任何這些前瞻性聲明。可能導致實際結果與前瞻性聲明中所述結果實質性差異的重要因素包括但不限於我們籌集資本以資助持續運營的能力;我們保護知識產權的能力;任何侵權訴訟或其他訴訟對我們帶來的影響;與其他供應商和產品的競爭;我們開發和商業化產品和服務的能力;政府監管的變化;我們完成融資交易的能力;以及與我們行業有關的其他因素,我們的業務和經營業績。實際結果可能與預期,相信,估計,預期,打算或計劃的結果有重大差異。可能導致我們實際結果與預期不符的因素或事件可能會時不時出現,我們無法預測其中的所有因素。我們無法保證未來的結果,活動水平,業績或成就。公司假設無義務更新任何前瞻性聲明以反映本發佈日期之後可能出現的任何事件或情況。




Investor Relations:

Dave Gentry
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447)
Or 407-644-4256
STSS@redchip.com



投資者關係:

Dave Gentry
RedChip Companies, Inc.
1-800-RED-CHIP (733-2447)
或407-644-4256
STSS@redchip.com



声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論